Background/aim-Carteolol is a adrenoceptor antagonist used topically to reduce intraocular pressure, typically twice daily. In an eVort to provide a once daily dosing regimen, carteolol was formulated with 1% alginic acid. The objective of this study was to evaluate the eYcacy and safety of carteolol alginate solution in comparison with standard carteolol solution.
Carteolol is a adrenoceptor antagonist with intrinsic sympathomimetic activity. Applied topically in patients with elevated intraocular pressure (IOP), it elicits a dose related decrease in IOP, with a maximum at 2%. 1 2 Applied twice daily, its ocular hypotensive eYcacy has been reported to be similar to that of timolol. 3 4 Glaucoma is for the most part an asymptomatic disease, and the treatments may elicit both local and systemic untoward eVects. Thus, it is a classic disease for which patient adherence with a medication regimen may be low. 5 In an eVort to reduce the dosing frequency for topical carteolol from the standard twice daily to once daily, carteolol was formulated with alginic acid. Alginate solution exhibits a viscosity low enough to be compatible with topical administration without blurring eVect. Sodium alginate is a natural polymer product with bioadhesive properties, 6 used in many pharmaceutical preparations including those for reflux oesophagitis. 7 In animals, an alginate formulation of carteolol 1% and 2% provides good intraocular delivery of carteolol, enhanced relative to standard solution. 8 In a water loaded rabbit model of aqueous humour dynamics, the alginate formulation of carteolol had a longer duration of action than the standard solution. 8 In a short term study in normal volunteers, the alginate formulation was found to be of similar comfort as the standard solution, with a possible longer duration of ocular hypotensive action.
The objective of this study was to evaluate the eYcacy and safety of carteolol alginate administered once daily in comparison with standard carteolol solution administered twice daily in a long term study.
Methods
This was a double masked, randomised, multicentre study, comparing two parallel treatment groups. Enrolled were adult patients with open angle glaucoma or ocular hypertension in one or both eyes. Patients using ocular hypotensive medication were required to undergo a washout as follows: adrenoceptor antagonists or sympathomimetics (3 weeks); latanoprost (1 week), pilocarpine, apraclonidine, or topical or oral carbonic anhydrase inhibitors (72 hours). For entry into the study the "study" eye(s) was (were) required to have an unmedicated IOP > 23 at 0900 or 1100 and < 32 mm Hg at 0900 and 1100. This study was reviewed by an institutional review board, and all patients provided written informed consent. Excluded from the study were patients with angle closure, congenital, secondary glaucoma, or advanced glaucoma; contact lens wear during the study; any intraocular infection or inflammation, ocular trauma, ocular surgery, or laser trabeculoplasty within the previous 3 months; previous intolerance to carteolol; or contraindications to the use of adrenoceptor antagonists (for example, asthma, chronic obstructive pulmonary disease, moderate to severe atrioventricular block unless a pacemaker was implanted, or bradycardia <45 bpm, etc). Ocular corticosteroid use during the study was prohibited. Patients who were using systemic medications such as adrenergic hypotension agents were allowed to participate if the condition and dosing regimen were stable. Also excluded were pregnant and lactating women.
A baseline examination was conducted, including measurements of heart rate and blood pressure, visual acuity, automated threshold visual field (if not performed within the previous 6 months), biomicroscopy, IOP measurement by Goldmann applanation at 0900 and 1100. After the last baseline IOP measurement, patients were assigned to receive, in a double masked fashion, either 2% carteolol alginate four times daily (∼0900) or standard 2% carteolol solution (Carteol, Laboratories Chauvin, Montpellier, France), twice daily (∼0900 and 2100). The randomisation code was prepared using the PROC RANUNI procedure (PC-SAS Version 6.12, SAS Institute, Cary, NC, USA) with a block size of four.
The composition of carteolol-alginate was identical to that of market carteolol, with the exception of the addition of 1% alginate. The formulations were identical in tonicity and viscosity. The pH of the solutions was similar. The vehicle for the carteolol-alginate group was formulated the same as the carteololalginate formulation, with the exception of carteolol. Patients used the medication in one or both eyes. The masking was maintained through the use of a vehicle in the evening for the alginate group. Patients were evaluated at baseline, 15, 60, and 120 days, with IOP measurements just before instillation of medication (0900) and 2 hours after in-oYce instillation of medication (1100). Slit lamp examinations were performed at each follow up examination, together with measurement of heart rate and blood pressure (1000) and ocular tolerance of the medication (1100). At day 120, visual acuity was assessed with the Snellen or decimal Monoyer scale, and visual fields were performed.
Statistical analysis of ocular hypotensive eYcacy was performed on the eye with the higher IOP at a mean of the 0900 and 1100 baseline, or, if equal, the right eye. With a sample size of 105 patients per treatment group, this study was planned for 95% power to detect a diVerence in treatments on IOP of 2 mm Hg, assuming a standard deviation of 4 mm Hg, 9 and a two tailed alpha of 0.05. The study also had 80% power to detect a treatment diVerence of 1.5 mm Hg. An overenrolment of approximately 5% was planned to account for any premature withdrawals or disqualifications. Both intent to treat and per protocol analyses were planned. Continuous measures were analysed using t test or Wilcoxon rank sum test depending on the distribution and ANOVA, and categorical measures were evaluated using the 2 test (PROC TTEST, PROC NPAR1WAY, PROC GLM AND PROC FREQ, PC-SAS). A priori, the primary eYcacy criterion was defined as the change from time relevant baseline IOP on day 60, a period by which the IOP on the new treatment should have stabilised. Equivalence tests were carried out following the methodology described by Grouin and Coste. 10 Two one sided t tests were performed. If both p values were inferior to 0.05, then equivalence between the two formulations was the conclusion.
Results
Entered into the study were 235 patients (115 standard and 120 alginate), plus one subject who did not return after day 0. In the standard group, five patients did not complete the study: lost to follow up (one), adverse events (two, dizziness, thorax pain and sweats of moderate intensity; and mild ocular irritation), worsening of disease (one), and cancellation of consent (one). In the alginate group a similar number of patients did not complete the trial: adverse events (three, tinnitus and watering of the eye; bradycardia; and dizziness-all judged mild or moderate), cancellation of consent (one), and poor compliance (one).
Patient demographics are shown in Table 1 . The population was 58% male with a mean age of 61 years, with iris colour distributed among blue-green-grey, hazel, and brown irides. Most patients were white. Approximately two thirds of the patients were diagnosed with primary open angle glaucoma (63.4%, 149/235), including three patients with pigmentary glaucoma (one in standard group and two in the alginate group). There were no statistically significant diVerences between treatment groups (p >0.22). Most (87%; 204/235) patients received treatment in both eyes. Also, most (64%, 151/235) patients were using at least one systemic medication. Before study entry, 51% of patients (120/235) were using an ocular hypotensive medication. For 102 of these patients, this medication was a topical adrenoceptor antagonist.
Mean intraocular pressure at 0900 and 1100 is shown in Figures 1 and 2 respectively, and mean change from baseline in intraocular pressure in Tables 2 and 3 .
From a baseline of approximately 24-25 mm Hg, mean reductions ranged from 5.5 to 6.5 mm to an IOP of approximately 18 mm Hg in both treatment groups. The ocular hypotensive eYcacy of carteolol was slightly greater at 1100, 2 hours after the last instillation, relative to 0900, approximately 24 or 12 hours after the last instillation of alginate or standard, respectively. The IOP course was statistically significant within time (time eVect: p=0.0001 in the repeated measures analysis). There was no evidence of drift with either treatment. In the equivalency analyses, all measures were within the plus or minus 2 mm Hg interval for equivalence and the two unilateral t tests were highly significant (p <0.005) at each time of evaluation.
Figure 1 Mean intraocular pressure (IOP) at 0900 (SD).
A per protocol analysis was performed on the 210 patients (102 in standard and 108 in alginate groups) without major protocol violations. Results were similar to the intent to treat analysis. The confidence intervals were (−0.57, +0.80) and (−0.46, 0.66) mm Hg for day 60 at 0900 and 1100, respectively.
No change was noted in distance visual acuity for 78.3% (90/115) of standard treated patients and in 70.0% (84/120) of alginate treated patients, without any statistically significant diVerence between the two treatment groups ( 2 , p = 0.20). Similar results were seen with fellow eye.
At day 120, visual fields were unchanged for 78.3% (90/115) of standard carteolol treated patients and 67.5% (81/120) of alginate treated patients for the study eye (p = 0.12 by 2 ). Adverse events were reported by 59 patients. Fifteen adverse events were assessed as drug related. Among these, four aVected the eye and adnexa: two in the standard group (one irritation and one worsening of dry eye) and two in the alginate group (one ocular irritation and one superficial punctate keratitis). Eleven nonophthalmic adverse events were assessed as drug related: five in the standard carteolol group and six in the alginate group. These adverse events were known possible blocker side eVects.
Two serious adverse events were reported during the study: unilateral worsening of existing age related macular degeneration (standard group) and hospitalisation for repair of hiatal hernia (alginate group). Neither was judged as drug related.
Subjective tolerance upon instillation was judged good or very good by 99% of alginate patients and by 98% of standard patients evaluated on day 120 (Table 4) . Discomfort was reported by approximately 10% to 15% of patients in each treatment group at each visit (Table 5) . These reports were similar in incidence in each group. The most frequent discomfort in both groups was a stinging sensation which generally lasted for a few seconds or a few minutes. The blurred vision sensation was recorded in 3/120 patients of the alginate group and 2/115 patients of the standard group.
At baseline, mean heart rate, systolic and diastolic blood pressure was approximately 73-74 bpm, 141-144 mm Hg, and 81-82 mm Hg, respectively. Slight decreases in means were observed at follow up visits (up to 6 bpm, 8 mm Hg, and 3 mm Hg, respectively). There were no statistically significant diVerences between treatment groups (p = 0.607 to 0.852).
Discussion
Evaluated at both peak and trough, at an initial, middle, and long term stage, the new alginate formulation once daily was equivalent in ocular hypotensive eYcacy to the standard solution formulation given twice daily. While a vehicle control would have been desirable, it is not possible to use in a chronic glaucoma study for ethical reasons. The positive control, standard carteolol solution, was similarly eVective in the present study (reduction of ∼ 6 mm Hg, or ∼25%) to that observed in previous studies. 2 4 11 Thus, the eYcacy of the positive control, and the high power of the study (95% to detect a 2 mm Hg diVerence) supports the statement of equivalency. Special attention is directed towards the 0900 hour measurement. This is ∼24 hours after the last dose of carteolol alginate, and yet the mean IOP is similar to the standard solution given 12 hours previously.
The ocular tolerance of the alginate was good. Again, it was similar to the standard formulation, which itself has been reported to be well tolerated. 12 13 Thus, the finding of no substantial comfort problems is also a positive attribute of the alginate. In particular, the incidence of blurred vision (less than 3% in each group) is much lower than what has been reported with timolol in gel forming solution. 13 With regard to safety, there was no significant diVerence between both treatment groups for all studied safety variables.
Both treatment groups experienced a slight decrease in mean heart rate and blood pressure. The intrinsic sympathomimetic activity of carteolol could explain the relatively small impact of carteolol on the cardiovascular function: carteolol has been shown to cause less bradycardia than timolol at night. 14 In our study, cardiovascular parameters were measured only once per visit, 1 hour after the morning instillation. Thus, it is not possible to discuss what occurred at other times for the 24 hours.
The relatively few adverse events were similar to those previously reported for this class of compounds. 15 16 In conclusion, the new alginate formulation of carteolol 2% given once daily was as eVective as standard carteolol given twice daily with no meaningful diVerences regarding safety. 
Collections Topic
Articles on similar topics can be found in the following collections 
METHOD AND RESULTS
Using the public Medline facility provided by the National Institutes of Health, the numbers of prospective studies and case reports published in the AJO and the BJO from January 1980 to December 1999 were determined. These were done using the following keyword searches: "prospective" and "case report." The countries of origin of the articles were counted manually for the years 1990 and 1999, and were taken as the addresses of the corresponding author. Keyword searching was not possible owing to the non-uniformity of the way the addresses were registered.
The total number of publications remained fairly constant in the AJO over the two decades (Fig 1A) . The percentage of prospective studies increased greatly from 1% to 12% (Fig 1B) . Case reports, on the other hand, constituted 34-45% of the published articles (Fig 1C) with no obvious trend.
In comparison, there was a steady increase in the total number of articles (Fig 1A) in the BJO. The trends in the percentages of prospective studies and of case reports were similar to that in the AJO (Fig 1B and C) . The native countries (that is, the countries in which the journals are published) were the major contributors of articles for their respective journals (Fig 2A) . The United States made a considerably larger contribution to the BJO than the United Kingdom did to the AJO (Fig 2B) . Comparing 1990 with 1999, the contribution from foreign countries had risen significantly from 40% to 60% in the BJO and from 14% to 36% in the AJO. The top few foreign countries contributing to the respective journals are shown in Figures 2C and D. 
COMMENT
In an ideal world, all studies will be randomised and controlled. In reality, however, this is often not the case for various reasons. In our present study, we arbitrarily and simplistically chose the prospective design as an indicator of a good quality publication. In both the BJO and the AJO, there had been an increasing percentage of prospective studies published (from 3% to 6% and from 1% to 12% respectively) over the past two decades. This is an encouraging sign but the percentages remain small, especially in the BJO, when compared with other types of publications. This is not necessarily the fault of the journals but merely a reflection of the research work done during that period
Contributions from abroad appeared to be on the increase in both journals when comparing 1990 with 1999 with the BJO Figure 1 Histograms showing (A) the total number of articles (B) There are limitations to the present study. The AJO and the BJO may not be representative of the international ophthalmic journals from the United States and the United Kingdom respectively. Secondly, the total number of articles may be deceptive as the BJO and the AJO may have articles such as book reviews, editorials, letters, etc at diVerent frequencies. Thirdly, there is the possibility of inadequate keyword classification of the publications in the journals. Finally, the address of the corresponding author may not always correspond to the country where the research was performed.
In conclusion, our study suggests that the standard of publications has improved in the AJO and the BJO, with an increasing international contribution over the past two decades. 16) and the text (p 922, line 8) the dose for carteolol alginate was given as "four times daily" when it should be once daily. We apologise for this error.
